Article Sidebar

Submitted
March 10, 2025
Accepted
September 1, 2025
Published
September 30, 2025
Download
PDF
Statistic
Read Counter : 416

Main Article Content

Abstract





Gene editing technologies such as have opened new avenues for studying the role of specific genes in cell survival and differentiation. In this study, we employed CRISPR-Cas9 to knock out the pro-apoptotic genes BAX and CASP3 in human induced pluripotent stem cells (hiPSCs). The edited cells were evaluated for viability, proliferation, and differentiation capacity using flow cytometry, qPCR, and lineage-specific markers. Results demonstrated enhanced cell survival under stress conditions and altered differentiation patterns favoring mesodermal lineage. These findings suggest that modulating apoptotic pathways in stem cells can significantly impact regenerative medicine strategies and improve cell-based therapies.





Keywords

CRISPR-Cas9 apoptosis, stem cells regenerative medicine gene editing

Article Details

License

Copyright (c) 2025 Zaman S. Hamza, Tiba Al Temimi, Ghadah Ali Al-Oudah, Kadum A. AlShareffi (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Zaman S. Hamza (2025) “CRISPR-Cas9 Mediated Knockout of Apoptotic Genes in Human Stem Cells: A Functional Study”, Journal of Biomedicine and Biochemistry, 4(3), pp. 48–70. doi:10.57238/jbb.2025.7432.1148.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

How to Cite

Zaman S. Hamza (2025) “CRISPR-Cas9 Mediated Knockout of Apoptotic Genes in Human Stem Cells: A Functional Study”, Journal of Biomedicine and Biochemistry, 4(3), pp. 48–70. doi:10.57238/jbb.2025.7432.1148.
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Wang B, Wang Z, Wang D, Zhang B, Ong SG, Li M, Yu W, Wang Y. krCRISPR: an easy and efficient strategy for generating conditional knockout of essential genes in cells. J Biol Eng. 2019;13:35. https://org.doi/10.1186/s13036-019-0150-y.
  2. Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21(2):121–131.https://org.doi/10.1038/nm.3793.
  3. Mandl M, Ritthammer H, Ejaz A, Wagner S, Hatzmann FM, Baumgarten S, et al. CRISPR/Cas9-mediated gene knockout in human adipose stem/progenitor cells. Adipocyte. 2020;9(1):626–35. https://org.doi/10.1080/21623945.2020.183423.
  4. Zhang Z, Zhang Y, Gao F, … (et al.). CRISPR/Cas9 genome-editing system in human stem cells: current status and future prospects. Mol Ther Nucleic Acids. 2017;9:230–241. https://org.doi/10.1016/j.omtn.2017.03.006.
  5. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–822. https://doi.org/10.1126/science.1225829.
  6. Asmamaw M, Zawdie B. Mechanism and applications of CRISPR/Cas-9-mediated genome editing. Biologics. 2021;15:353–361.
  7. Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:1143157. https://org.doi/0.3389/fbioe.2023.1143157.
  8. Xue C, Greene EC. DNA repair pathway choices in CRISPR-Cas9-mediated genome editing. Trends Genet. 2021;37(7):639–656. https://org.doi/10.1016/j.tig.2021.04.008.
  9. Wang Z, Zhang Y, Lee YW, Ivanova NB. Combining CRISPR/Cas9-mediated knockout with genetic complementation for in-depth mechanistic studies in human ES cells. BioTechniques. 2019;66(1):23–7. https://org.doi/10.2144/btn-2018-011.
  10. Sánchez Martín MA, García-Tuñón I. CRISPR-ERA for switching off (onco)genes. In: Singh A, editor. Modulating Gene Expression: Abridging the Gap between Basic and Applied Research. London: InTechOpen; 2018. p. 1–10.
  11. Guo T, Feng YL, Xiao JJ, … (et al.). Harnessing accurate non-homologous end joining for efficient, precise deletion in CRISPR/Cas9-mediated genome editing. Genome Biol. 2018;19:170. https://org.doi/10.1186/s13059-018-1550-x.
  12. Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z. Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol. 2011;103:55–98. https://org.doi/ 10.1016/B978-0-12-385493-3.00004-8
  13. Mandl M, Ritthammer H, Ejaz A, et al. CRISPR/Cas9-mediated gene knockout in human adipose stem/progenitor cells. Adipocyte. 2020;9(1):626–635. https://org.doi/10.1080/21623945.2020.1834230
  14. Mahajan A, Sharma G, Thakur K, Raza K, Gurpal G, Katare OP. Autoimmune diseases and apoptosis: Targets, challenges, and innovations. IUBMB Life. 2021;73(7):825–38. https://org.doi/10.1002/iub.2472.
  15. Yi H, Sogah K, Boyce M, Degterev A, Christofferson DE, Yuan J. A genome-wide RNAi screen reveals multiple regulators of caspase activation. J Cell Biol. 2007;179(4):619–26. https://org.doi/10.1083/jcb.200708090.
  16. Hassan M, Matuschek C, Gerber PA, Peiper M, Budach W, Bölke E, et al. Identification of candidate genes with pro-apoptotic properties by functional screening of randomly fragmented cDNA libraries. Eur J Med Res. 2010;15(4):162–8.https://org.doi/10.1186/2047-783X-15-4-16.
  17. Greer YE, Gilbert SF, Gril B, Narwal R, Peacock Brooks DL, Tice DA, Steeg PS, Lipkowitz S. MEDI3039, a novel highly potent TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist, causes regression of orthotopic tumors… Breast Cancer Res. 2019;21:27. https://org.doi/10.1186/s13058-018-1089-2.
  18. Deglincerti A, … (et al.). Self-organization of the in vitro attached human embryo. Nature. 2016;533:251–254. https://org.doi/10.1038/nature17948.
  19. Pera MF. Human embryo research and the 14-day rule. Development. 2017;144:1923–1925. https://org.doi/10.1242/dev.153445.
  20. Harrison SE, Sozen B, Christodoulou N, Kyprianou C, Zernicka-Goetz M. Assembly of embryonic and extraembryonic stem cells to mimic embryogenesis in vitro. Science. 2017;356(6334):eaal1810. https://org.doi/10.1126/science.aal181.
  21. Chen L, Shi K, Qiu W, Aagaard L, Kassem M. Generation of inducible CRISPRi and CRISPRa human stromal/stem cell lines for controlled target gene transcription during lineage differentiation. Stem Cells Int. 2020;2020:8857344. https://org.doi/10.1155/2020/8857344.
  22. Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578(7794):229–236. https://org.doi/10.1038/s41586-020-1978-5.
  23. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158. https://org.doi/10.1126/science.aam7344.
  24. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689–698. https://org.doi/10.1038/nrc1691.
  25. Evers B, Helleday T, Jonkers J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci. 2010;31(8):372–380. https://org.doi/10.1016/j.tips.2010.06.001
  26. O’Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer. Nat Rev Genet. 2017;18(10):613–623. https://org.doi/10.1038/nrg.2017.47
  27. Chan N, Bristow RG. “Contextual” synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res. 2010;16(18):4553–4560. https://org.doi/10.1158/1078-0432.CCR-10-0527
  28. McLornan DP, List A, Mufti GJ. Applying synthetic lethality for the selective targeting of cancer. N Engl J Med. 2014;371(18):1725–1735. https://org.doi/10.1056/NEJMra1407390.
  29. Morgens DW, Deans RM, Li A, Bassik MC. Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. Nat Biotechnol. 2016;34(6):634–636. https://org.doi/10.1038/nbt.3567
  30. Kampmann M. CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine. ACS Chem Biol. 2018;13(2):406–416. https://org.doi/10.1021/acschembio.7b00657.
  31. Kearns NA, Genga RM, Enuameh MS, Garber M, Wolfe SA, Maehr R. Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. Development. 2014;141(1):219–223. https://org.doi/10.1242/dev.103341.
  32. Thakore PI, D’Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, … Gersbach CA. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods. 2015;12(12):1143–1149. https://org.doi/10.1038/nmeth.3630.
  33. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173–1183. https://org.doi/10.1016/j.cell.2013.02.022.
  34. Kampmann M, Bassik MC, Weissman JS. Integrated platform for genome-wide screening and construction of high-density genetic interaction maps in mammalian cells. Proc Natl Acad Sci USA. 2013;110(25):E2317–E2326. https://org.doi/10.1073/pnas.1307002110.
  35. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, … Weissman JS. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154(2):442–451. https://org.doi/10.1016/j.cell.2013.06.044.
  36. Xu X, Chemparathy A, Zeng L, Kempton HR, Shang S, Nakamura M, Qi LS. Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing. Mol Cell. 2021;81(20):4333–4345.e4. https://org.doi/10.1016/j.molcel.2021.08.008.
  37. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, … Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA. 1987;84(21):7413–7417. https://org.doi/10.1073/pnas.84.21.7413.
  38. Zaborowska I, Bański P, Białkowska A, … (et al.). Recent advances in non-viral methods of gene delivery. Acta Biochim Pol. 2012;59(3):403–418.
  39. Xu Y, Liang W, Qiu Y, … (et al.). Non-viral delivery systems for CRISPR/Cas9 in vivo. Theranostics. 2019;9(24):6926–6948. https://org.doi/10.7150/thno.38016.
  40. Wilbie D, Walther J, Mastrobattista E. Delivery aspects of CRISPR/Cas for in vivo genome editing. Acc Chem Res. 2019;52(6):1555–1564. https://org.doi/10.1021/acs.accounts.9b00106.
  41. Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25(1):1234–1257. https://org.doi/10.1080/10717544.2018.1474964.
  42. Glass Z, Lee M, Li Y, Xu Q. Engineering the delivery system for CRISPR-based genome editing. Trends Biotechnol. 2018;36(2):173–185. https://org.doi/10.1016/j.tibtech.2017.11.006.
  43. Mout R, Ray M, Yesilbag Tonga G, Lee YW, Tay T, Rotello VM. Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing. ACS Nano. 2017;11(3):2452–2458. https://org.doi/10.1021/acsnano.6b07600.
  44. Miller JB, Zhang S, Kos P, Xiong H, Zhou K, Perelman SS, Zhu H, Siegwart DJ. Non-viral CRISPR/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA. Angew Chem Int Ed Engl. 2017;56(4):1059–1063. https://org.doi/10.1002/anie.201610209.
  45. Chen R, Huang H, Liu H, Xi J, Ning J, Zeng W, Shen C, Zhang T, Yu G, Xu Q, Wang J, Xu L, Liang Z, Wang Y. Friend or foe? Evidence emerges of the complicated interactions between CRISPR/Cas9 and cancer. Signal Transduct Target Ther. 2018;3:30. https://org.doi/10.1038/s41392-018-0038-9.
  46. Akram F, Haq IU, Ahmed R, Shoukat A, Ilyas M, Rashid N, Numan M, Wang X. CRISPR-Cas9: A tool to eradicate multidrug-resistant Gram-negative pathogens. Front Microbiol. 2023;14:1118440. https://org.doi/10.3389/fmicb.2023.1118440.
  47. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014;15(5):321–334. https://org.doi/10.1038/nrg3686.
  48. Wright AV, Nuñez JK, Doudna JA. Biology and applications of CRISPR systems: harnessing nature’s toolbox for genome engineering. Cell. 2016;164(1-2):29–44. https://org.doi/10.1016/j.cell.2015.12.035.
  49. Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490–507. https://org.doi/10.1038/s41580-019-0131-5.
  50. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823–826. https://org.doi/10.1126/science.1232033.
  51. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262–1278. https://org.doi/10.1016/j.cell.2014.05.010.
  52. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. https://org.doi/10.1126/science.1258096.
  53. Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. Nat Biotechnol. 2016;34(9):933–941. https://org.doi/10.1038/nbt.3659.
  54. Komor AC, Badran AH, Liu DR. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell. 2017;169(3):559. https://org.doi/10.1016/j.cell.2017.04.005 .
  55. Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361(6405):866–869. https://org.doi/10.1126/science.aat5011.
  56. Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018;9:1911. https://org.doi/10.1038/s41467-018-04252-2.
  57. Carroll D, Charo RA. The societal opportunities and challenges of genome editing. Genome Biol. 2015;16:242. https://org.doi/10.1186/s13059-015-0812-0.
  58. Lander ES. The heroes of CRISPR. Cell. 2016;164(1-2):18–28. https://org.doi/10.1016/j.cell.2015.12.041.
  59. Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016;539(7630):479. https://org.doi/10.1038/nature.2016.20988.
  60. Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016;24(3):430–446. https://org.doi/10.1038/mt.2016.10.
  61. Kaiser J. Human germline genome editing: the debate continues. Science. 2015;348(6230):1306–1307. https://org.doi/10.1126/science.348.6230.1306.
  62. Carroll D. Genome editing: past, present, and future. Yale J Biol Med. 2017;90(4):653–659. PMID: 29259528
  63. Porteus MH. A new class of medicines through DNA editing. N Engl J Med. 2019;380(10):947–959. https://org.doi/10.1056/NEJMra1800729.
  64. Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359(6372):eaan4672. https://org.doi/10.1126/science.aan4672 .
  65. Li L, Hu S, Chen X. Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities. Biomaterials. 2018;171:207–218. https://org.doi/10.1016/j.biomaterials.2018.04.031.
  66. Wang HX, Song Z, Lao YH, Xu X, Gong J, Cheng D, Chakraborty S, Park JS, Li M, Huang D, Yin H, Cheng J. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide. Proc Natl Acad Sci USA. 2018;115(19):4903–4908. https://org.doi/10.1073/pnas.1711293115.
  67. Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25(1):1234–1257. https://org.doi/10.1080/10717544.2018.1474964.
  68. Mout R, Ray M, Lee YW, Scaletti F, Rotello VM. In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: progress and challenges. Bioconjug Chem. 2017;28(4):880–884. https://org.doi/10.1021/acs.bioconjchem.7b00057.
  69. Nelson CE, Gersbach CA. Engineering delivery vehicles for genome editing. Annu Rev Chem Biomol Eng. 2016;7:637–662. https://org.doi/10.1146/annurev-chembioeng-080615-034711.
  70. Wang M, Zuris JA, Meng F, Rees H, Sun S, Deng P, Han Y, Gao X, Pouli D, Wu Q, Georgakoudi I, Liu DR, Xu Q. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci USA. 2016;113(11):2868–2873. https://org.doi/10.1073/pnas.1520244113.
  71. Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, Dirstine T, Ciullo C, Lescarbeau R, Seitzer J, Shah RR, Shah A, Ling D, Growe J, Pink M, Rohde E, Wood KM, Salomon WE, Harrington WF, Dombrowski C, Strapps WR, Chang Y, Morrissey DV. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Mol Ther. 2018;26(9):1973–1983. https://org.doi/10.1016/j.ymthe.2018.05.001.
  72. Wang P, Zhang L, Xie Y, Wang N, Tang R, Zheng W, Jiang X, Jiang W, Yang H. Genome editing for cancer therapy: delivery of Cas9 protein/sgRNA plasmid via a gold nanocluster/lipid core-shell nanocarrier. Adv Sci. 2017;4(11):1700175. https://org.doi/10.1002/advs.201700175.
  73. Sun W, Ji W, Hall JM, Hu Q, Wang C, Beisel CL, Gu Z. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed Engl. 2015;54(41):12029–12033. https://org.doi/10.1002/anie.201506030.
  74. Lee K, Conboy M, Park HM, Jiang F, Kim HJ, Dewitt MA, Mackley VA, Chang K, Rao A, Skinner C, Shobha T, Mehdipour M, Liu H, Huang WC, Lan F, Bray NL, Li S, Corn JE, Kataoka K, Doudna JA, Conboy IM, Murthy N. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng. 2017;1:889–901. https://org.doi/10.1038/s41551-017-0137-2.
  75. Glass Z, Lee M, Li Y, Xu Q. Engineering the delivery system for CRISPR-based genome editing. Trends Biotechnol. 2018;36(2):173–185. https://org.doi/10.1016/j.tibtech.2017.11.006.
  76. Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25(1):1234–1257. https://org.doi/10.1080/10717544.2018.1474964.
  77. Wilbie D, Walther J, Mastrobattista E. Delivery aspects of CRISPR/Cas for in vivo genome editing. Acc Chem Res. 2019;52(6):1555–1564. https://doi.org/10.1021/acs.accounts.9b00106.
  78. Xu CF, Wang J. Delivery systems for CRISPR/Cas9 gene editing. Adv Drug Deliv Rev. 2021;168:3–4. https://doi.org/10.1016/j.addr.2020.12.004.
  79. Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, Maeder ML, Joung JK, Chen ZY, Liu DR. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol. 2015;33(1):73–80. https://doi.org/10.1038/nbt.3081.
  80. Staahl BT, Benekareddy M, Coulon-Bainier C, Banfal AA, Floor SN, Sabo JK, Urnes C, Munares GA, Ghosh A, Doudna JA. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat Biotechnol. 2017;35(5):431–434. https://doi.org/10.1038/nbt.3806.
  81. Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A, Gupta A, Bolukbasi MF, Walsh S, Bogorad RL, Gao G, Weng Z, Dong Y, Koteliansky V, Wolfe SA, Langer R, Xue W, Anderson DG. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016;34(3):328–333. https://doi.org/10.1038/nbt.3471.
  82. Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, Carte J, Chen W, Roark N, Ranganathan S, Ravinder N, Chesnut JD. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol. 2015;208:44–53. https://doi.org/10.1016/j.jbiotec.2015.04.024.
  83. Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24(6):1012–1019. https://doi.org/10.1101/gr.171322.113.
  84. Ramakrishna S, Kwaku Dad AB, Beloor J, Gopalappa R, Lee SK, Kim H. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 2014;24(6):1020–1027. https://doi.org/10.1101/gr.171264.113.
  85. Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, Maeder ML, Joung JK, Chen ZY, Liu DR. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol. 2015;33(1):73–80. https://doi.org/10.1038/nbt.3081.
  86. Staahl BT, Benekareddy M, Coulon-Bainier C, Banfal AA, Floor SN, Sabo JK, Urnes C, Munares GA, Ghosh A, Doudna JA. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat Biotechnol. 2017;35(5):431–434. https://doi.org/10.1038/nbt.3806.
  87. Liu J, Chang J, Jiang Y, Meng X, Sun T, Mao L, Xu Q, Wang M, Chen H, Small B, Qin J, Gong N, Yu X, Gao Y. Fast and efficient genome editing in human pluripotent stem cells by delivery of Cas9 ribonucleoproteins. Cell Rep. 2018;22(11):2526–2538. https://doi.org/10.1016/j.celrep.2018.02.018.
  88. Chen F, Ding X, Feng Y, Seebeck T, Jiang Y, Davis GD. Targeted activation of diverse CRISPR-Cas systems for mammalian genome editing via delivery of Cas9 protein and sgRNA. Mol Ther Nucleic Acids. 2017;8:528–536. https://doi.org/10.1016/j.omtn.2017.07.009 .
  89. Mout R, Ray M, Yesilbag Tonga G, Lee YW, Tay T, Sasaki K, Rotello VM. Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing. ACS Nano. 2017;11(3):2452–2458. https://doi.org/10.1021/acsnano.6b07600.
  90. Alghuthaymi MA, Almoammar H, Rai M, Said-Galiev E, Abd-Elsalam KA. Myconanoparticles: synthesis and their role in phytopathogens management. Biotechnol Biotechnol Equip. 2015;29(2):221–236. https://doi.org/10.1080/13102818.2015.1008194.
  91. Gupta P, Diwan B. Bacterial exopolysaccharide mediated heavy metal removal: a review on biosynthesis, mechanism and remediation strategies. Biotechnol Reports. 2017;13:58–71. https://doi.org/10.1016/j.btre.2016.12.006.
  92. Narayanan KB, Sakthivel N. Biological synthesis of metal nanoparticles by microbes. Adv Colloid Interface Sci. 2010;156(1-2):1–13. https://doi.org/10.1016/j.cis.2010.02.001.
  93. Singh P, Kim YJ, Zhang D, Yang DC. Biological synthesis of nanoparticles from plants and microorganisms. Trends Biotechnol. 2016;34(7):588–599. https://doi.org/10.1016/j.tibtech.2016.02.006.
  94. Iravani S. Bacteria in nanoparticle synthesis: current status and future prospects. Int Sch Res Notices. 2014;2014:359316. https://doi.org/10.1155/2014/359316.
  95. Roy A, Bulut O, Some S, Mandal AK, Yilmaz MD. Green synthesis of silver nanoparticles: biomolecule-nanoparticle organizations targeting antimicrobial activity. RSC Adv. 2019;9(5):2673–2702. https://doi.org/10.1039/C8RA08982E.
  96. Gudikandula K, Vadapally P, Charya MAS. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gram-negative bacteria. Nanomedicine: NBM. 2017;13(1):103–110. https://doi.org/10.1016/j.nano.2016.08.008
  97. Ssekatawa K, Byarugaba DK, Kisaalita WS, Nnyago H, Luboobi LS, Wampande E, Kateete DP, Nakavuma JL, Waako PJ. Potential therapeutic applications of nanoparticles in different bacterial infections. Appl Microbiol Biotechnol. 2021;105(4):1333–1348. https://doi.org/10.1007/s00253-020-11025-y
  98. Pantidos N, Horsfall LE. Biological synthesis of metallic nanoparticles by bacteria, fungi and plants. J Nanomed Nanotechnol. 2014;5(5):233. https://doi.org/10.4172/2157-7439.1000233

Similar Articles

You may also start an advanced similarity search for this article.